The primary endpoint was the mean change in the lesion area from baseline to month 18 as measured by fundus autofluorescence ( 79 ).” The results showed a trend for a reduction in GA progression of 20% in the lampalizumab group, but there was no significant difference between the lampalizumab and sham groups ( 79 ).
← all excerpts
The Challenges and Promise of Complement Therapeutics for Ocular Diseases.
1
—
—